At a glance
ClinicalIndex Comparison RecordN/ACompleted· 1,802 enrolled
Drug / intervention
tolvaptandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD in Japan
In Brief
An observational study evaluating tolvaptan for Polycystic Kidney, Autosomal Dominant. Completed, enrolled 1,802 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the safety and effectiveness of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD) in the real world clinical setting in Japan.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPolycystic Kidney, Autosomal Dominant
CountriesJapan
Collaborators--
Timeline
N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartMar 2014
First PostedJul 2016
Primary CompletionSep 2022
TodayJul 2026
First PostedJul 28, 2016
Enrollment StartMar 24, 2014
Primary CompletionSep 20, 2022
TodayJul 2, 2026
Enrollment to primary: 8.5 yearsPosted 9.9 years ago
Interventions
tolvaptandrug